Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients

被引：8

作者：

Hu, Bei ^{[1
,3
]}

Lin, Xiao ^{[1
,11
]}

Lee, Hans C. ^{[1
]}

Huang, Xuelin ^{[4
]}

Tidwell, Rebecca S. Slack ^{[4
]}

Ahn, Kwang Woo ^{[5
,6
]}

Hu, Zhen-Huan ^{[5
]}

Jabbour, Elias ^{[1
]}

Verstovsek, Srdan ^{[1
]}

Ravandi, Farhad ^{[1
]}

Garcia-Manero, Guillermo ^{[1
]}

Kharfan-Dabaja, Mohamed A. ^{[7
]}

Hossain, Nasheed M. ^{[8
]}

Marks, David I. ^{[9
]}

Kamble, Rammuriti T. ^{[10
]}

Inamoto, Yoshihiro ^{[12
]}

Kindwall-Keller, Tamila ^{[13
]}

Saad, Ayman ^{[14
]}

Litzow, Mark R. ^{[15
,16
]}

Savani, Bipin N. ^{[17
]}

Hale, Gregory A. ^{[18
]}

Bacher, Ulrike ^{[19
]}

Gerds, Aaron T. ^{[20
]}

Liesveld, Jane L. ^{[21
]}

Ustun, Celalettin ^{[22
]}

Olsson, Richard F. ^{[23
,24
]}

Daly, Andrew ^{[25
]}

Grunwald, Michael R. ^{[3
]}

Solh, Melhem ^{[26
]}

DeFilipp, Zachariah ^{[27
]}

Aljurf, Mahmoud ^{[29
]}

Wirk, Baldeep ^{[30
]}

Akpek, Gorgun ^{[31
]}

Nishihori, Taiga ^{[32
]}

Cerny, Jan ^{[33
]}

Seo, Sachiko ^{[34
]}

Hsu, Jack W. ^{[35
]}

Champlin, Richard ^{[36
]}

de Lima, Marcos ^{[37
]}

Alyea, Edwin ^{[38
]}

Popat, Uday ^{[1
]}

Sobecks, Ronald ^{[20
]}

Scott, Bart L. ^{[39
]}

Kantarjian, Hagop ^{[28
]}

Cortes, Jorge ^{[2
]}

Saber, Wael ^{[5
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA

[2] Georgia Canc Ctr, 1410 Laney Walker Rd,CN2222, Augusta, GA 30912 USA

[3] Levine Canc Inst Atrium Hlth, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA

[4] MD Anderson Canc Ctr, Dept Biostat, Houston, TX USA

[5] CIBMTR Ctr Int Blood & Marrow Transplant Res, Med Coll Wisconsin, Dept Med, Milwaukee, WI USA

[6] Med Coll Wisconsin, Inst Hlth & Equity, Div Biostat, Milwaukee, WI USA

[7] Mayo Clin, Div Hematol Oncol, Blood & Marrow Transplant Program, Jacksonville, FL USA

[8] Loyola Univ, Chicago Stritch Sch Med, Maywood, IL USA

[9] Univ Hosp Bristol NHS Trust, Bristol, England

[10] Baylor Coll Med, Ctr Cell & Gene Therapy, Div Hematol Oncol, Houston, TX USA

[11] China Phamaceut, Res Ctr Biostat & Computat Pharm, Nanjing, Juangsu, Peoples R China

[12] Natl Canc Ctr, Div Hematopoietic Stem Cell Transplantat, Tokyo, Japan

[13] Univ Virgina Hlth Syst, Div Hematol Oncol, Charlottesville, VA USA

[14] Ohio State Univ, Div Hematol, Columbus, OH USA

[15] Mayo Clin Rochester, Div Hematol, Rochester, MN USA

[16] Mayo Clin Rochester, Transplant Ctr, Rochester, MN USA

[17] Vanderbilt Univ, Dept Med, Div Hematol Oncol, Nashville, TN USA

[18] Johns Hopkins Childrens Hosp, Dept Hematol Oncol, Petersbug, FL USA

[19] Bern Univ Hosp, Dept Hematol Inselspital, Bern, Switzerland

[20] Cleveland Clin, Taussig Canc Inst, Hematol & Med Oncol, Cleveland, OH USA

[21] Univ Rochester Med Ctr, Dept Med, Rochester, NY USA

[22] Rush Univ, Div Hematol Oncol Cell Therapy, Chicago, IL USA

[23] Karolinska Inst, Dept Lab Med, Stockholm, Sweden

[24] Uppsala Univ, Ctr Clin Res Sormland, Uppsala, Sweden

[25] Tom Baker Canc Clin, Calgary, AB, Canada

[26] Northside Hosp, Blood & Marrow Transplant Grp Georgia, Atlanta, GA USA

[27] Massachusetts Gen Hosp, Blood & Marrow Transplant Program, Boston, MA USA

[28] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Div Canc Med, Houston, TX USA

[29] King Faisal Specialist Hosp Ctr & Res, Dept Oncol, Riyadh, Saudi Arabia

[30] Seattle Canc Care Alliance, Div Bone Marrow Transplant, Seattle, WA USA

[31] Rush Univ Med Ctr, Stem Cell Transplantat & Cell Therapy, Dept Internal Med, Chicago, IL USA

[32] H Lee Moffitt Canc & Res Inst, Dept Blood & marrow Transplantat, Tampa, FL USA

[33] Univ Massachusetts Med Ctr, Dept Med, Div Hematol Oncol, Worcester, MA USA

[34] Dokkyo Med Univ, Dept Hematol Oncol, Tochigi, Japan

[35] Shands HealthCare & Univ Florida, Div Hematol Oncol, Dept Med, Gainesville, FL USA

[36] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Div Canc Med, Houston, TX USA

[37] Univ Hosp Case Med Ctr, Seidman Canc Ctr, Dept Med, Cleveland, OH USA

[38] Dana Farber Canc Inst, Ctr Hematol Oncol, Boston, MA USA

[39] Fred Hutchinson Canc Res Ctr, Seattle, WA USA

来源：

LEUKEMIA & LYMPHOMA | 2020年 / 61卷 / 12期

关键词：

Chronic myeloid leukemia; allogeneic stem cell transplant; tyrosine kinase inhibitors; CHRONIC MYELOGENOUS LEUKEMIA; WORLD-HEALTH-ORGANIZATION; ABL TYROSINE KINASE; LOW-DOSE CYTARABINE; CHRONIC-PHASE; IMATINIB; DISCONTINUATION; INTERFERON; INHIBITOR; SURVIVAL;

D O I：

10.1080/10428194.2020.1783444

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

While TKI are the preferred first-line treatment for chronic phase (CP) CML, alloHCT remains an important consideration. The aim is to estimate residual life expectancy (RLE) for patients initially diagnosed with CP CML based on timing of alloHCT or continuation of TKI in various settings: CP1 CML, CP2 + [after transformation to accelerated phase (AP) or blast phase (BP)], AP, or BP. Non-transplant cohort included single-institution patients initiating TKI and switched TKI due to failure. CIBMTR transplant cohort included CML patients who underwent HLA sibling matched (MRD) or unrelated donor (MUD) alloHCT. AlloHCT appeared to shorten survival in CP1 CML with overall mortality hazard ratio (HR) for alloHCT of 2.4 (95% CI 1.2-4.9;p = .02). In BP CML, there was a trend toward higher survival with alloHCT; HR = 0.7 (0.5-1.1;p = .099). AlloHCT in CP2 + [HR = 2.0 (0.8-4.9),p = .13] and AP [HR = 1.1 (0.6-2.1);p = .80] is less clear and should be determined on a case-by-case basis.

引用

页码：2811 / 2820

页数：10

共 50 条

[31] Risk factors for adverse outcome in patients with Chronic Lymphocytic Leukemia (CLL) undergoing Allogeneic Hematopoietic Cell Transplantation (alloHCT): A Retrospective EBMT Analysis
Schetelig, J.
de Wreede, L.
Moreno, C.
Andersen, N. Smedegaard
van Gelder, M.
Machaczka, M.
Gramatzki, M.
Dreger, P.
Vitek, A.
Karas, M.
Michallet, M.
Henseler, A.
Bornhaeuser, M.
Schoenland, S.
Kroeger, N.
BONE MARROW TRANSPLANTATION, 2015, 50 : S107 - S108
[32] Outcomes of Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Monosomal Karyotypes
Moon, Joon Ho
Lee, Yoo Jin
Seo, Sang Kyung
Han, Seo Ae
Yoon, Joon Seok
Ham, Ji Yeon
Suh, Jang Soo
Sohn, Sang Kyun
ACTA HAEMATOLOGICA, 2015, 133 (04) : 327 - 335
[33] Allogeneic hematopoietic cell transplantation for patients with a history of multiple relapses of acute myeloid leukemia
Masamitsu Yanada
Jinichi Mori
Jun Aoki
Masayoshi Masuko
Kaito Harada
Naoyuki Uchida
Noriko Doki
Takahiro Fukuda
Toru Sakura
Heiwa Kanamori
Masashi Sawa
Tadakazu Kondo
Yuta Katayama
Junya Kanda
Tatsuo Ichinohe
Yoshiko Atsuta
Shingo Yano
Annals of Hematology, 2019, 98 : 2179 - 2186
[34] Impact of allogeneic hematopoietic cell transplantation on the outcome of older patients with acute myeloid leukemia
Appelbaum, Frederick R.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2017, 30 (04) : 320 - 326
[35] Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adult Patients with Acute Myeloid Leukemia
Mizuno, Shohei
Takami, Akiyoshi
Kawamura, Koji
Arai, Yasuyuki
Kondo, Tadakazu
Kawata, Takahito
Uchida, Naoyuki
Marumo, Atsushi
Fukuda, Takahiro
Tanaka, Masatsugu
Ozawa, Yukiyasu
Yoshida, Shuro
Ota, Shuichi
Takada, Satoru
Sawa, Masashi
Onizuka, Makoto
Kanda, Yoshinobu
Ichinohe, Tatsuo
Atsuta, Yoshiko
Yanada, Masamitsu
TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (04): : 314.e1 - 314.e10
[36] Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia
Prateek Pophali
Aasiya Matin
Abhishek A. Mangaonkar
Ryan Carr
Moritz Binder
Aref Al-Kali
Kebede H. Begna
Kaaren K. Reichard
Hassan Alkhateeb
Mithun V. Shah
Ayalew Tefferi
William J. Hogan
Mark R. Litzow
Mrinal M. Patnaik
Blood Cancer Journal, 10
[37] Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia
Pophali, Prateek
Matin, Aasiya
Mangaonkar, Abhishek A.
Carr, Ryan
Binder, Moritz
Al-Kali, Aref
Begna, Kebede H.
Reichard, Kaaren K.
Alkhateeb, Hassan
Shah, Mithun V.
Tefferi, Ayalew
Hogan, William J.
Litzow, Mark R.
Patnaik, Mrinal M.
BLOOD CANCER JOURNAL, 2020, 10 (11)
[38] ROLE OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MONOSOMAL KARYOTYPE
Choi, Y.
Kim, S. D.
Kim, D. Y.
Lee, J. H.
Lee, K. H.
Seol, M.
Lee, Y. S.
Kang, Y. A.
Jeon, M.
Jung, A. R.
Lee, J. H.
HAEMATOLOGICA, 2012, 97 : 30 - 30
[39] Allogeneic hematopoietic cell transplantation for patients with a history of multiple relapses of acute myeloid leukemia
Yanada, Masamitsu
Mori, Jinichi
Aoki, Jun
Masuko, Masayoshi
Harada, Kaito
Uchida, Naoyuki
Doki, Noriko
Fukuda, Takahiro
Sakura, Toru
Kanamori, Heiwa
Sawa, Masashi
Kondo, Tadakazu
Katayama, Yuta
Kanda, Junya
Ichinohe, Tatsuo
Atsuta, Yoshiko
Yano, Shingo
ANNALS OF HEMATOLOGY, 2019, 98 (09) : 2179 - 2186
[40] ROLE OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Kim, D. Y.
Lee, J. H.
Lee, J. H.
Lim, S. N.
Kim, S. D.
Choi, Y.
Lee, K. H.
Kim, J. Y.
Lee, Y. S.
Kang, Y. A.
Seol, M.
Jeon, M.
Lee, Y. J.
Lee, K. H.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 646 - 646

← 1 2 3 4 5 →